{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T13:51:43Z","timestamp":1773323503469,"version":"3.50.1"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2011,11,6]],"date-time":"2011-11-06T00:00:00Z","timestamp":1320537600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancer Chemother Pharmacol"],"published-print":{"date-parts":[[2012,3]]},"DOI":"10.1007\/s00280-011-1770-1","type":"journal-article","created":{"date-parts":[[2011,11,5]],"date-time":"2011-11-05T07:22:40Z","timestamp":1320477760000},"page":"825-834","source":"Crossref","is-referenced-by-count":8,"title":["A phase I pharmacokinetic study of bexarotene with paclitaxel and carboplatin in patients with advanced non-small cell lung cancer (NSCLC)"],"prefix":"10.1007","volume":"69","author":[{"given":"Jordi","family":"Rodon","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Charlotte D.","family":"Jacobs","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Quincy","family":"Chu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eric K.","family":"Rowinsky","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arturo","family":"Lopez-Anaya","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chris H.","family":"Takimoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Heather A.","family":"Wakelee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2011,11,6]]},"reference":[{"issue":"3","key":"1770_CR1","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1038\/35106036","volume":"1","author":"L Altucci","year":"2001","unstructured":"Altucci L, Gronemeyer H (2001) The promise of retinoids to fight against cancer. Nat Rev Cancer 1(3):181\u2013193","journal-title":"Nat Rev Cancer"},{"issue":"1","key":"1770_CR2","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/S1040-8428(01)00144-5","volume":"41","author":"SY Sun","year":"2002","unstructured":"Sun SY, Lotan R (2002) Retinoids and their receptors in cancer development and chemoprevention. Crit Rev Oncol Hematol 41(1):41\u201355","journal-title":"Crit Rev Oncol Hematol"},{"issue":"15","key":"1770_CR3","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1056\/NEJM199710093371501","volume":"337","author":"MS Tallman","year":"1997","unstructured":"Tallman MS, Andersen JW, Schiffer CA, Appelbaum FR, Feusner JH, Ogden A, Shepherd L, Willman C, Bloomfield CD, Rowe JM, Wiernik PH (1997) All-trans-retinoic acid in acute promyelocytic leukemia. N Engl J Med 337(15):1021\u20131028","journal-title":"N Engl J Med"},{"issue":"36","key":"1770_CR4","doi-asserted-by":"crossref","first-page":"5703","DOI":"10.1200\/JCO.2006.08.1596","volume":"24","author":"L Ades","year":"2006","unstructured":"Ades L, Chevret S, Raffoux E, de Botton S, Guerci A, Pigneux A, Stoppa AM, Lamy T, Rigal-Huguet F, Vekhoff A, Meyer-Monard S, Maloisel F, Deconinck E, Ferrant A, Thomas X, Fegueux N, Chomienne C, Dombret H, Degos L, Fenaux P (2006) Is cytarabine useful in the treatment of acute promyelocytic leukemia? Results of a randomized trial from the European Acute Promyelocytic Leukemia Group. J Clin Oncol 24(36):5703\u20135710","journal-title":"J Clin Oncol"},{"issue":"4","key":"1770_CR5","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.1182\/blood.V94.4.1192","volume":"94","author":"P Fenaux","year":"1999","unstructured":"Fenaux P, Chastang C, Chevret S, Sanz M, Dombret H, Archimbaud E, Fey M, Rayon C, Huguet F, Sotto JJ, Gardin C, Makhoul PC, Travade P, Solary E, Fegueux N, Bordessoule D, Miguel JS, Link H, Desablens B, Stamatoullas A, Deconinck E, Maloisel F, Castaigne S, Preudhomme C, Degos L (1999) A randomized comparison of all transretinoic acid (ATRA) followed by chemotherapy and ATRA plus chemotherapy and the role of maintenance therapy in newly diagnosed acute promyelocytic leukemia. The European APL Group. Blood 94(4):1192\u20131200","journal-title":"Blood"},{"issue":"11","key":"1770_CR6","doi-asserted-by":"crossref","first-page":"3241","DOI":"10.1182\/blood.V82.11.3241.3241","volume":"82","author":"P Fenaux","year":"1993","unstructured":"Fenaux P, Le Deley MC, Castaigne S, Archimbaud E, Chomienne C, Link H, Guerci A, Duarte M, Daniel MT, Bowen D et al (1993) Effect of all transretinoic acid in newly diagnosed acute promyelocytic leukemia. Results of a multicenter randomized trial. European APL 91 Group. Blood 82(11):3241\u20133249","journal-title":"Blood"},{"issue":"2","key":"1770_CR7","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1046\/j.1440-0960.2001.00488.x","volume":"42","author":"HM Prince","year":"2001","unstructured":"Prince HM, McCormack C, Ryan G, Baker C, Rotstein H, Davison J, Yocum R (2001) Bexarotene capsules and gel for previously treated patients with cutaneous T-cell lymphoma: results of the Australian patients treated on phase II trials. Australas J Dermatol 42(2):91\u201397","journal-title":"Australas J Dermatol"},{"issue":"5","key":"1770_CR8","first-page":"581","volume":"137","author":"M Duvic","year":"2001","unstructured":"Duvic M, Martin AG, Kim Y, Olsen E, Wood GS, Crowley CA, Yocum RC (2001) Phase 2 and 3 clinical trial of oral bexarotene (Targretin capsules) for the treatment of refractory or persistent early-stage cutaneous T-cell lymphoma. Arch Dermatol 137(5):581\u2013593","journal-title":"Arch Dermatol"},{"issue":"5","key":"1770_CR9","first-page":"1731","volume":"6","author":"SL Soignet","year":"2000","unstructured":"Soignet SL, Miller VA, Pfister DG, Bienvenu BJ, Ho R, Parker BA, Amyotte SA, Cato A III, Warrell RP Jr (2000) Initial clinical trial of a high-affinity retinoic acid receptor ligand (LGD1550). Clin Cancer Res 6(5):1731\u20131735","journal-title":"Clin Cancer Res"},{"issue":"7","key":"1770_CR10","first-page":"1658","volume":"5","author":"NA Rizvi","year":"1999","unstructured":"Rizvi NA, Marshall JL, Dahut W, Ness E, Truglia JA, Loewen G, Gill GM, Ulm EH, Geiser R, Jaunakais D, Hawkins MJ (1999) A Phase I study of LGD1069 in adults with advanced cancer. Clin Cancer Res 5(7):1658\u20131664","journal-title":"Clin Cancer Res"},{"issue":"2","key":"1770_CR11","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1200\/JCO.1997.15.2.790","volume":"15","author":"VA Miller","year":"1997","unstructured":"Miller VA, Benedetti FM, Rigas JR, Verret AL, Pfister DG, Straus D, Kris MG, Crisp M, Heyman R, Loewen GR, Truglia JA, Warrell RP Jr (1997) Initial clinical trial of a selective retinoid X receptor ligand, LGD1069. J Clin Oncol 15(2):790\u2013795","journal-title":"J Clin Oncol"},{"issue":"1","key":"1770_CR12","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1634\/theoncologist.10-1-22","volume":"10","author":"JR Rigas","year":"2005","unstructured":"Rigas JR, Dragnev KH (2005) Emerging role of rexinoids in non-small cell lung cancer: focus on bexarotene. Oncologist 10(1):22\u201333","journal-title":"Oncologist"},{"issue":"22","key":"1770_CR13","doi-asserted-by":"crossref","first-page":"12070","DOI":"10.1073\/pnas.94.22.12070","volume":"94","author":"J Langenfeld","year":"1997","unstructured":"Langenfeld J, Kiyokawa H, Sekula D, Boyle J, Dmitrovsky E (1997) Posttranslational regulation of cyclin D1 by retinoic acid: a chemoprevention mechanism. Proc Natl Acad Sci USA 94(22):12070\u201312074","journal-title":"Proc Natl Acad Sci USA"},{"issue":"15","key":"1770_CR14","first-page":"5919","volume":"61","author":"JI Song","year":"2001","unstructured":"Song JI, Lango MN, Hwang JD, Drenning SD, Zeng Q, Lamph WW, Grandis JR (2001) Abrogation of transforming growth factor-alpha\/epidermal growth factor receptor autocrine signaling by an RXR-selective retinoid (LGD1069, Targretin) in head and neck cancer cell lines. Cancer Res 61(15):5919\u20135925","journal-title":"Cancer Res"},{"issue":"31","key":"1770_CR15","doi-asserted-by":"crossref","first-page":"22013","DOI":"10.1074\/jbc.274.31.22013","volume":"274","author":"MJ Spinella","year":"1999","unstructured":"Spinella MJ, Freemantle SJ, Sekula D, Chang JH, Christie AJ, Dmitrovsky E (1999) Retinoic acid promotes ubiquitination and proteolysis of cyclin D1 during induced tumor cell differentiation. J Biol Chem 274(31):22013\u201322018","journal-title":"J Biol Chem"},{"issue":"12","key":"1770_CR16","doi-asserted-by":"crossref","first-page":"9728","DOI":"10.1074\/jbc.M110897200","volume":"277","author":"JF Sah","year":"2002","unstructured":"Sah JF, Eckert RL, Chandraratna RA, Rorke EA (2002) Retinoids suppress epidermal growth factor-associated cell proliferation by inhibiting epidermal growth factor receptor-dependent ERK1\/2 activation. J Biol Chem 277(12):9728\u20139735","journal-title":"J Biol Chem"},{"issue":"3","key":"1770_CR17","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1002\/pros.20347","volume":"66","author":"WC Yen","year":"2006","unstructured":"Yen WC, Lamph WW (2006) A selective retinoid X receptor agonist bexarotene (LGD1069, Targretin) prevents and overcomes multidrug resistance in advanced prostate cancer. Prostate 66(3):305\u2013316","journal-title":"Prostate"},{"issue":"1","key":"1770_CR18","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.lungcan.2005.05.008","volume":"50","author":"TW Hermann","year":"2005","unstructured":"Hermann TW, Yen WC, Tooker P, Fan B, Roegner K, Negro-Vilar A, Lamph WW, Bissonnette RP (2005) The retinoid X receptor agonist bexarotene (Targretin) synergistically enhances the growth inhibitory activity of cytotoxic drugs in non-small cell lung cancer cells. Lung Cancer 50(1):9\u201318","journal-title":"Lung Cancer"},{"issue":"5","key":"1770_CR19","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1158\/1535-7163.MCT-05-0018","volume":"4","author":"WC Yen","year":"2005","unstructured":"Yen WC, Lamph WW (2005) The selective retinoid X receptor agonist bexarotene (LGD1069, Targretin) prevents and overcomes multidrug resistance in advanced breast carcinoma. Mol Cancer Ther 4(5):824\u2013834","journal-title":"Mol Cancer Ther"},{"issue":"24","key":"1770_CR20","doi-asserted-by":"crossref","first-page":"8656","DOI":"10.1158\/1078-0432.CCR-04-0979","volume":"10","author":"WC Yen","year":"2004","unstructured":"Yen WC, Corpuz MR, Prudente RY, Cooke TA, Bissonnette RP, Negro-Vilar A, Lamph WW (2004) A selective retinoid X receptor agonist bexarotene (Targretin) prevents and overcomes acquired paclitaxel (Taxol) resistance in human non-small cell lung cancer. Clin Cancer Res 10(24):8656\u20138664","journal-title":"Clin Cancer Res"},{"issue":"2","key":"1770_CR21","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1007\/s10549-004-1426-5","volume":"88","author":"WC Yen","year":"2004","unstructured":"Yen WC, Prudente RY, Lamph WW (2004) Synergistic effect of a retinoid X receptor-selective ligand bexarotene (LGD1069, Targretin) and paclitaxel (Taxol) in mammary carcinoma. Breast Cancer Res Treat 88(2):141\u2013148","journal-title":"Breast Cancer Res Treat"},{"issue":"11","key":"1770_CR22","doi-asserted-by":"crossref","first-page":"1879","DOI":"10.1200\/JCO.2007.12.2689","volume":"26","author":"GR Blumenschein Jr","year":"2008","unstructured":"Blumenschein GR Jr, Khuri FR, von Pawel J, Gatzemeier U, Miller WH Jr, Jotte RM, Le Treut J, Sun SL, Zhang JK, Dziewanowska ZE, Negro-Vilar A (2008) Phase III trial comparing carboplatin, paclitaxel, and bexarotene with carboplatin and paclitaxel in chemotherapy-naive patients with advanced or metastatic non-small-cell lung cancer: SPIRIT II. J Clin Oncol 26(11):1879\u20131885","journal-title":"J Clin Oncol"},{"issue":"3","key":"1770_CR23","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1515\/DMDI.2003.19.3.161","volume":"19","author":"H Fujino","year":"2003","unstructured":"Fujino H, Yamada I, Shimada S, Hirano M, Tsunenari Y, Kojima J (2003) Interaction between fibrates and statins\u2014metabolic interactions with gemfibrozil. Drug Metabol Drug Interact 19(3):161\u2013176","journal-title":"Drug Metabol Drug Interact"},{"issue":"2","key":"1770_CR24","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1067\/mcp.2000.108507","volume":"68","author":"JT Backman","year":"2000","unstructured":"Backman JT, Kyrklund C, Kivisto KT, Wang JS, Neuvonen PJ (2000) Plasma concentrations of active simvastatin acid are increased by gemfibrozil. Clin Pharmacol Ther 68(2):122\u2013129","journal-title":"Clin Pharmacol Ther"},{"issue":"6A","key":"1770_CR25","first-page":"2273","volume":"14","author":"AH Calvert","year":"1994","unstructured":"Calvert AH (1994) Dose optimisation of carboplatin in adults. Anticancer Res 14(6A):2273\u20132278","journal-title":"Anticancer Res"},{"issue":"2","key":"1770_CR26","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1056\/NEJMoa011954","volume":"346","author":"JH Schiller","year":"2002","unstructured":"Schiller JH, Harrington D, Belani CP, Langer C, Sandler A, Krook J, Zhu J, Johnson DH (2002) Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med 346(2):92\u201398","journal-title":"N Engl J Med"},{"key":"1770_CR37","unstructured":"Flockhart DA (2007) Drug interactions: cytochrome P450 drug interaction table. Indiana University School of Medicine. http:\/\/medicine.iupui.edu\/clinpharm\/ddis\/table.asp . Accessed 26 Jan 2010"},{"key":"1770_CR38","unstructured":"Guidance for Industry Drug Interaction Studies\u2014Study Design, Data Analysis, and Implications for Dosing and Labeling (2006) U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER), Center for Biologics Evaluation and Research (CBER), September 2006"},{"key":"1770_CR39","doi-asserted-by":"crossref","unstructured":"Zhang YY, Liu Y, Zhang JW, Ge GB, Wang LM, Sun J, Yang L (2009) Characterization of human cytochrome P450 isoforms involved in the metabolism of 7-epi-paclitaxel. Xenobiotica 39(4):283\u2013292","DOI":"10.1080\/00498250802714907"},{"key":"1770_CR40","doi-asserted-by":"crossref","unstructured":"Wakelee HA, Middleton G, Dunlop D, Ramlau R, Leighl N, Hao D, Lopez-Anaya A, Zatloukal P, Jacobs CD (2011) A phase I pharmacokinetic study of bexarotene with vinorelbine and cisplatin in patients with advanced nonsmall-cell lung cancer (NSCLC). doi: 10.1007\/s00280-011-1771-0","DOI":"10.1007\/s00280-011-1771-0"},{"issue":"11","key":"1770_CR27","doi-asserted-by":"crossref","first-page":"1886","DOI":"10.1200\/JCO.2007.12.2614","volume":"26","author":"R Ramlau","year":"2008","unstructured":"Ramlau R, Zatloukal P, Jassem J, Schwarzenberger P, Orlov SV, Gottfried M, Pereira JR, Temperley G, Negro-Vilar R, Rahal S, Zhang JK, Negro-Vilar A, Dziewanowska ZE (2008) Randomized phase III trial comparing bexarotene (L1069\u201349)\/cisplatin\/vinorelbine with cisplatin\/vinorelbine in chemotherapy-naive patients with advanced or metastatic non-small-cell lung cancer: SPIRIT I. J Clin Oncol 26(11):1886\u20131892","journal-title":"J Clin Oncol"},{"issue":"16s","key":"1770_CR28","first-page":"648s","volume":"23","author":"R Govindan","year":"2005","unstructured":"Govindan R, Crowley J, Schwartzbberg L, Kennedy P, Ekstrand BC, Sandler A, Juanakais D, Ghalie R (2005) Phase II trial of bexarotene capsules in patients with non-small-cell lung cancer (NSCLC) who have failed at least 2 prior systemic therapies for Stage IIIB\/IV disease. J Clin Oncol 23(16s):648s Abstract #7116","journal-title":"J Clin Oncol"},{"issue":"34","key":"1770_CR29","doi-asserted-by":"crossref","first-page":"8757","DOI":"10.1200\/JCO.2005.01.9521","volume":"23","author":"KH Dragnev","year":"2005","unstructured":"Dragnev KH, Petty WJ, Shah S, Biddle A, Desai NB, Memoli V, Rigas JR, Dmitrovsky E (2005) Bexarotene and erlotinib for aerodigestive tract cancer. J Clin Oncol 23(34):8757\u20138764","journal-title":"J Clin Oncol"},{"issue":"1","key":"1770_CR30","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1158\/1535-7163.MCT-06-0125","volume":"6","author":"Y Kato","year":"2007","unstructured":"Kato Y, Salumbides BC, Wang XF, Qian DZ, Williams S, Wei Y, Sanni TB, Atadja P, Pili R (2007) Antitumor effect of the histone deacetylase inhibitor LAQ824 in combination with 13-cis-retinoic acid in human malignant melanoma. Mol Cancer Ther 6(1):70\u201381","journal-title":"Mol Cancer Ther"},{"issue":"15","key":"1770_CR31","doi-asserted-by":"crossref","first-page":"5047","DOI":"10.1021\/jm058214k","volume":"48","author":"LK Gediya","year":"2005","unstructured":"Gediya LK, Chopra P, Purushottamachar P, Maheshwari N, Njar VC (2005) A new simple and high-yield synthesis of suberoylanilide hydroxamic acid and its inhibitory effect alone or in combination with retinoids on proliferation of human prostate cancer cells. J Med Chem 48(15):5047\u20135051","journal-title":"J Med Chem"},{"issue":"6","key":"1770_CR32","first-page":"4019","volume":"24","author":"L Emionite","year":"2004","unstructured":"Emionite L, Galmozzi F, Grattarola M, Boccardo F, Vergani L, Toma S (2004) Histone deacetylase inhibitors enhance retinoid response in human breast cancer cell lines. Anticancer Res 24(6):4019\u20134024","journal-title":"Anticancer Res"},{"issue":"9","key":"1770_CR33","first-page":"3591","volume":"61","author":"DC Coffey","year":"2001","unstructured":"Coffey DC, Kutko MC, Glick RD, Butler LM, Heller G, Rifkind RA, Marks PA, Richon VM, La Quaglia MP (2001) The histone deacetylase inhibitor, CBHA, inhibits growth of human neuroblastoma xenografts in vivo, alone and synergistically with all-trans retinoic acid. Cancer Res 61(9):3591\u20133594","journal-title":"Cancer Res"},{"issue":"1","key":"1770_CR34","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1124\/mol.106.022954","volume":"70","author":"SJ Lee","year":"2006","unstructured":"Lee SJ, Yang EK, Kim SG (2006) Peroxisome proliferator-activated receptor-gamma and retinoic acid X receptor alpha represses the TGFbeta1 gene via PTEN-mediated p70 ribosomal S6 kinase-1 inhibition: role for Zf9 dephosphorylation. Mol Pharmacol 70(1):415\u2013425","journal-title":"Mol Pharmacol"},{"issue":"4","key":"1770_CR35","first-page":"977","volume":"28","author":"H Murad","year":"2006","unstructured":"Murad H, Collet P, Huin-Schohn C, Al-Makdissy N, Kerjan G, Chedotal A, Donner M, Devignes MD, Becuwe P, Schohn H, Domenjoud L, Dauca M (2006) Effects of PPAR and RXR ligands in semaphorin 6B gene expression of human MCF-7 breast cancer cells. Int J Oncol 28(4):977\u2013984","journal-title":"Int J Oncol"},{"issue":"5","key":"1770_CR36","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1016\/S0009-9236(03)00006-7","volume":"73","author":"CB Washington","year":"2003","unstructured":"Washington CB, Flexner C, Sheiner LB, Rosenkranz SL, Segal Y, Aberg JA, Blaschke TF (2003) Effect of simultaneous versus staggered dosing on pharmacokinetic interactions of protease inhibitors. Clin Pharmacol Ther 73(5):406\u2013416","journal-title":"Clin Pharmacol Ther"}],"container-title":["Cancer Chemotherapy and Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-011-1770-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00280-011-1770-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-011-1770-1","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,6,27]],"date-time":"2020-06-27T03:59:46Z","timestamp":1593230386000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00280-011-1770-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,11,6]]},"references-count":40,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2012,3]]}},"alternative-id":["1770"],"URL":"https:\/\/doi.org\/10.1007\/s00280-011-1770-1","relation":{},"ISSN":["0344-5704","1432-0843"],"issn-type":[{"value":"0344-5704","type":"print"},{"value":"1432-0843","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,11,6]]}}}